Chinese investors specializing in healthcare are increasingly expanding into the European market with a series of high-profile, strategic investments. This is part of a trend of heightened healthcare deal activity from Chinese investors. Last year, companies based in China announced acquisitions in the medical industry worth 30.4 billion USD – representing twice the investment level of 2014.
French pharmaceutical company Etypharm has attracted a number of Chinese bidders, including Luye Group Ltd., the company that controls Luye Pharma, a Chinese drugmaker and healthcare provider. Luye Pharma’s product portfolio includes medication designed to treat cancer and cardiovascular disease, and it reported a net income of 116.4 million USD in 2015.
Luye Group has stated that it is pursuing overseas healthcare acquisitions in order to tap into rising demand for high-quality medical services in China, particularly from the increasingly affluent Chinese middle class. According to the IMS Institute for Healthcare Informatics, over 115 billion USD worth of drugs were sold in China in 2015, making it the second-largest market in the world after the US.
Etypharm is owned by private-equity firm Astorg Partners, and it is estimated to sell for 785 million USD or more.
Chinese investors who are planning to make significant deployments in the global healthcare market often turn to trusted facilitators to source high-potential opportunities. Naseba has spent over a decade building close relationships with investors around the world, including China. Our analysts conduct daily phone calls with Chinese investors, and fully understand their needs and mandates.
On December 7th, 2016, in Shanghai, Naseba will be organising the European Healthcare Investment Meeting. At the meeting, pre-screened Chinese investors will be introduced to pre-qualified European healthcare opportunities.
Submit your business case:
Oops! We could not locate your form.
To learn more, contact:
Naseba investor introduction
+971 4 455 7954